Prostate cancer is often found in the late stage, which not only takes a life, but also brings a broken family; Fortunately, the Ministry of Health and Welfare has approved the indications of a new generation of oral hormone drugs, which provides a new treatment choice for patients with "high-risk non-metastatic castration-resistant prostate cancer", avoids chemotherapy discomfort and prolongs the metastasis-free survival time for more than 3 years. It is really a great blessing for patients!
Chemotherapy is no longer the only choice for the new generation of oral hormone therapy!
Jiang Bohui, chairman of the Taiwan Province Medical Association of Urology Oncology, said that according to the statistical report of the Ministry of Health and Welfare in 20 1 year,1man was diagnosed with prostate cancer. At present, there are many methods to treat prostate cancer, about 60% of which take hormone therapy, but the traditional hormone therapy will fail because of drug resistance for more than one year on average. This kind of patients is clinically called "castration-resistant prostate cancer", and the average time from effective hormone therapy to death is less than 2-3 years.
Chairman Jiang Bohui explained that in the past, once drug resistance appeared in traditional hormone therapy, dorsal chemotherapy was the only treatment option, but the curative effect of chemotherapy was limited, and the side effects such as fear of hair loss, numbness of hands and feet, nausea and vomiting were even more daunting; Once the disease worsens, patients will face the dilemma of no medicine available. Fortunately, in recent years, many new generation hormone therapy drugs have come out one after another, so that patients who have failed chemotherapy can continue to use them; In addition, it can also be used for patients who are not suitable for chemotherapy, significantly prolonging the life of patients and improving their quality of life.
A new generation of oral hormone non-metastatic patients is also applicable!
Chief physician Jiang Bohui said that when the patient's PSA index doubles ≤ 10 month, the risk of metastasis will increase. At the same time, due to the limitations of current diagnostic techniques, more than 30% of patients are actually metastatic castration-resistant prostate cancer, but they can't be diagnosed in time and miss the opportunity to take the right medicine. In order to solve this treatment dilemma, the Ministry of Health approved the indication of a new generation of oral hormone drugs for the treatment of "high-risk non-metastatic castration-resistant prostate cancer" this year, so that more high-risk patients have the opportunity to take drugs as soon as possible to delay the deterioration and metastasis of cancer.
Chairman Jiang Bohui emphasized that the significance of delaying cancer metastasis in high-risk patients lies in prolonging patients' survival and also represents delaying cancer-related deaths. It is pointed out that the new generation of oral hormone drugs can delay the deterioration time of PSA and avoid chemotherapy for patients with non-metastatic castration-resistant prostate cancer. The median survival time is over three years, which not only greatly shortens the time for patients to receive chemotherapy, but also means that the cancer is controlled without deterioration. The most important thing is to provide the longest use time of oral hormone drugs and improve the quality of life, which is undoubtedly a new breakthrough in treatment!
Chairman Jiang Bohui added that there are two kinds of oral hormone drugs for the treatment of non-metastatic castration-resistant prostate cancer, one of which is a new drug just listed this year; Another drug has been on the market for a long time, and doctors have rich experience in using it, and it has been proved that it is also suitable for patients with severe liver dysfunction, with low side effects and good safety. Director Jiang reminded that patients with abnormal liver function often worry about the safety of medication, and suggested that if patients have liver function problems at the same time, they should discuss appropriate treatment plans with doctors.
Join us and pay attention to your health every day! Line @ ID: @ Subscribe to healthy Aloha audio-visual channel to read health knowledge more easily: /beauty/article/42737 Keywords: Jiang Bohui, prostate cancer, a new generation of oral hormones, cancer, castration-resistant prostate cancer, urology oncology of Taiwan Province Medical Association.